



SAFETY DATA SHEET

Revision date: 19-Jul-2018

Version: 4.1

Page 1 of 9

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Clindamycin Palmitate Hydrochloride for Oral Solution

Trade Name: Cleocin Pediatric Flavored Granules; Dalacin C Flavored Granules; Sobelin
Synonyms: Dalacin C Syrup
Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as antibiotic agent

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Skin Sensitization: Category 1

US OSHA Specific - Classification

Physical Hazard: Combustible Dust

Label Elements

Signal Word: Warning
Hazard Statements: H317 - May cause an allergic skin reaction
May form combustible dust concentrations in air

Precautionary Statements: P261 - Avoid breathing dust/fume/gas/mist/vapors/spray
P272 - Contaminated work clothing must not be allowed out of the workplace
P280 - Wear protective gloves/protective clothing/eye protection/face protection
P302+ P352 - IF ON SKIN: Wash with plenty of soap and water
P333 + P313 - If skin irritation or rash occurs: Get medical advice/attention
P321 - Specific treatment (see supplemental first aid instructions on this label)
P363 - Wash contaminated clothing before reuse
P501 - Dispose of contents/container in accordance with all local and national regulations

SAFETY DATA SHEET

Material Name: Clindamycin Palmitate Hydrochloride for Oral Solution
Revision date: 19-Jul-2018

Page 2 of 9

Version: 4.1



Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Clindamycin Hydrochloride Palmitate	25507-04-4	Not Listed	Skin Sens.1 (H317)	3.8
Sucrose	57-50-1	200-334-9	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Cherry flavor, artificial	NOT ASSIGNED	Not Listed	Not Listed	*
Dextrin	9004-53-9	232-675-4	Not Listed	*
Simethicone	8050-81-5	Not Listed	Not Listed	*
Poloxalene	9003-11-6	Not Listed	Not Listed	*
Ethylparaben	120-47-8	204-399-4	Not Listed	*

Additional Information:

* Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact:

Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact:

Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion:

Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation:

Remove to fresh air and keep patient at rest. Seek medical attention immediately.

SAFETY DATA SHEET

Material Name: Clindamycin Palmitate Hydrochloride for Oral Solution
Revision date: 19-Jul-2018

Page 3 of 9

Version: 4.1

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure:	For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
Medical Conditions Aggravated by Exposure:	None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO₂, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

SAFETY DATA SHEET

Material Name: Clindamycin Palmitate Hydrochloride for Oral Solution
Revision date: 19-Jul-2018

Page 4 of 9

Version: 4.1

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Clindamycin Hydrochloride Palmitate

Pfizer OEL TWA-8 Hr: 100µg/m³, (as free base)

Sucrose

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Australia TWA	10 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Bulgaria OEL - TWA	10.0 mg/m ³
Estonia OEL - TWA	10 mg/m ³
France OEL - TWA	10 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
Latvia OEL - TWA	5 mg/m ³
Lithuania OEL - TWA	10 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Slovakia OEL - TWA	6 mg/m ³
Spain OEL - TWA	10 mg/m ³

Simethicone

Pfizer Occupational Exposure Band (OEB): OEB 1 (control exposure to the range of 1000ug/m³ to 3000ug/m³)

Exposure Controls

Engineering Controls:	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.
Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.
Hands:	Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)
Eyes:	Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)
Skin:	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)
Respiratory protection:	Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

SAFETY DATA SHEET

Material Name: Clindamycin Palmitate Hydrochloride for Oral Solution
Revision date: 19-Jul-2018

Page 5 of 9

Version: 4.1

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Granules	Color:	No data available.
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture

Solvent Solubility:	No data available
Water Solubility:	No data available
Solubility:	Soluble: Water
pH:	No data available.
Melting/Freezing Point (°C):	No data available
Boiling Point (°C):	No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

Clindamycin Hydrochloride Palmitate

No data available

Sucrose

No data available

Cherry flavor, artificial

No data available

Dextrin

No data available

Ethylparaben

No data available

Simethicone

No data available

Poloxalene

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available

Flammability (Solids): No data available

Flash Point (Liquid) (°C): No data available

Upper Explosive Limits (Liquid) (% by Vol.): No data available

Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition Products: No data available

SAFETY DATA SHEET

Material Name: Clindamycin Palmitate Hydrochloride for Oral Solution
Revision date: 19-Jul-2018

Page 6 of 9

Version: 4.1

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information:

The information included in this section describes the potential hazards of the individual ingredients.

Known Clinical Effects:

Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions. Pseudomembranous colitis (manifested by watery diarrhea, urge to defecate, abdominal cramps, low-grade fever, bloody stools, and abdominal pain) may also occur. Effects on blood and blood-forming organs have also occurred.

Acute Toxicity: (Species, Route, End Point, Dose)

Clindamycin Hydrochloride Palmitate

Rat Oral LD 50 > 5000 mg/kg
Rat Para-periosteal LD 50 > 5000mg/kg
Rat Intraperitoneal LD 50 > 2500mg/kg
Mouse Oral LD 50 > 5000mg/kg
Mouse Intravenous LD 50 > 5000mg/kg

Sucrose

Rat Oral LD50 29.7 g/kg

Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Clindamycin Hydrochloride Palmitate

6 Month(s) Rat Oral 600 mg/kg/day NOAEL No effects at maximum dose
6 Month(s) Dog Oral 300 mg/kg/day NOAEL No effects at maximum dose

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Clindamycin Hydrochloride Palmitate

Reproductive & Fertility Rat Oral 300 mg/kg/day NOAEL Negative, No effects at maximum dose
Embryo / Fetal Development Mouse Oral 600 mg/kg/day NOAEL Not Teratogenic, No effects at maximum dose

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Clindamycin Hydrochloride Palmitate

Bacterial Mutagenicity (Ames) *Salmonella* Negative
Micronucleus Rat Negative

Sucrose

Bacterial Mutagenicity (Ames) *Salmonella* Negative

Carcinogen Status:

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

SAFETY DATA SHEET

Material Name: Clindamycin Palmitate Hydrochloride for Oral Solution
Revision date: 19-Jul-2018

Page 7 of 9

Version: 4.1

12. ECOLOGICAL INFORMATION

Environmental Overview:	Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.
Toxicity:	No data available
Persistence and Degradability:	No data available
Bio-accumulative Potential:	No data available
Mobility in Soil:	No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Clindamycin Hydrochloride Palmitate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed
Cherry flavor, artificial	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed

SAFETY DATA SHEET

Material Name: Clindamycin Palmitate Hydrochloride for Oral
Solution
Revision date: 19-Jul-2018

Page 8 of 9

Version: 4.1

15. REGULATORY INFORMATION

EU EINECS/ELINCS List	Not Listed
Dextrin	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	232-675-4
Sucrose	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	200-334-9
Simethicone	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed
Poloxalene	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed
Ethylparaben	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	204-399-4

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Sensitization, skin-Cat.1; H317 - May cause an allergic skin reaction

Data Sources: Publicly available toxicity information. Safety data sheets for individual ingredients. Pfizer proprietary drug development information.

SAFETY DATA SHEET

Material Name: Clindamycin Palmitate Hydrochloride for Oral Solution

Page 9 of 9

Revision date: 19-Jul-2018

Version: 4.1

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 7 - Handling and Storage.

Revision date: 19-Jul-2018

Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet